Cube Labs S.p.a. · MIL:CUBE
Cube Labs — Investor Presentation (October 2026)
47 slides from Cube Labs's investor presentation, October 2026
Slide 1: Corporate Presentation
CORPORATE PRESENTATION
Slide 2: Disclaimer
DISCLAIMER CONFIDENTIALITY This Document has been drafted by Cube Labs S.p.A. (hereinafter the "Company") solely for the purpose of this presentation. The Document may not be reproduced or distributed, in whole or in part, by any person other than the Company. The Company assumes no responsibility f
Slide 3: Founders
FOUNDERS Renato Del Grosso Massimo Fiocchi Filippo Surace Co-Founder & Co-Founder & Founder & CEO Chief Strategy Officer Chief Financial Officer EDUCATION AND TRAINING EDUCATION AND TRAINING EDUCATION AND TRAINING KEY PROFESSIONAL EXPERIENCE KEY PROFESSIONAL EXPERIENCE KEY PROFESSIONAL EXPERIENCE 3
Slide 4: Index
INDEX 1 COMPANY OVERVIEW p. 5 2 BUSINESS MODEL p. 13 3 SPIN-OFF PORTFOLIO p. 18 4 IPO p. 27 5 CAPITAL INCREASE p. 32 6 FINANCIAL RESULTS p. 35 7 ESG IMPACT p. 38 8 APPENDIX: TEAM AND p. 41 STRATEGIC ADVISORY BOARD
Slide 5: Company Overview
MaAIAdSAAO L ANVdUWOD
Slide 6: Cube Labs at a Glance
CUBE LABS AT A GLANCE Cube Labs S.p.A. is an Italian Venture Builder specialized in the development of projects in the healthcare technologies sector. Cube Labs has been listed since March 21, 2023 on Euronext Growth Milan - Professional segment, dedicated to SMEs with high growth potential. 3 offic
Slide 7: Our Figures and Network
OUR FIGURES AND NETWORK 20 24 57M€ Portfolio Companies2 60+ International Universities in INBB Assets Patents and Licenses Consortium Value1 700 88 154M€ Researchers in INBB Research Centers in CNR Portfolio Ecosystem Network Valuation3 1. Updated as of 30 June 2026. 2. Includes Serescentia S.r.l.,
Slide 8: Governance and Shareholding
GOVERNANCE AND SHAREHOLDING BOARD OF DIRECTORS Filippo Surace Chairman and CEO Renato Del Grosso Massimo Fiocchi Member of Board Member of Board Domenico Colella Giuseppina Staropoli Non-executive Director Independent Director AUDITING FIRM F. Surace* Free Float** ** of which 7.69% is held by 60.50%
Slide 9: Development Strategy
DEVELOPMENT STRATEGY SHORT TERM STRATEGY MID-LONG TERM STRATEGY VALORIZATION OF THE SUBSIDIARY COMPANIES R&D ACTIVITIES ON ADDITIONAL INITIATIVES BY INCREASING R&D ACTIVITY ON SELECTED ALREADY IN THE PORTFOLIO INITIATIVES CORPORATE FINANCE & Cube Labs intends to increase its R&D activity in COMMERCI
Slide 10: Our Story
OUR STORY 2013 Cube Labs Incorporation • Pilot program and scientific networking; 2014 - 2016 • Blue ocean expansion in China, Spain and CEE. • 10 new portfolio companies in partnership with I.N.B.B.; 2017 - 2020 • Expansion in Switzerland and Israel; • Seed investment by CDP VC SGR in 4 spin-offs.
Slide 11: Global Footprint
GLOBAL FOOTPRINT Italy France Poland Spain Germany China Italy Italy USA Israel India 11
Slide 12: Accelerating ESG Impact
ACCELERATING ESG IMPACT DEMOCRATIZATION ACCESSIBILITY A HEALTHIER FUTURE Pervasive knowledge as a Life Sciences accessible to all. Our ESG approach for a healthier widespread economic advantage. Our vision, our tangible future. Promoting innovation The technology transfer through commitment. and sup
Slide 13: Business Model
BUSINESS 2 MODEL
Slide 14: Our Venture Building Approach
OUR VENTURE BUILDING APPROACH Cube Labs builds new companies from promising R&D activities, transforming pioneering science into real-world healthcare solutions. As a venture builder, it supports selected projects from their earliest stages: BUILDING FINANCING GROWTH We provide We source proprietary
Slide 15: Business Model
BUSINESS MODEL Cube Labs is a shareholder of subsidiaries that hold academic research projects that have passed the Proof of Concept (PoC), and that come mainly from the partnership with INBB. The Company selects academic projects with high development potential. A key point of Cube Labs’ business m
Slide 16: Key Success Factors
KEY SUCCESS FACTORS FIRST MOVER SUCCESSFUL TEAM HIGH DEGREE OF CONTROL Experts with international Cube Labs is the first venture experience in both industry- From the initial stages builder in healthcare sector, leading companies and to the commercialization listed on EGM – Professional top academic
Slide 17: Revenue Model
REVENUE MODEL Innovative revenues model with streamline from spin-offs to the Holding enabling Cube Labs to be independent from continuous capital injections in order to improve its spin-offs portfolio up to the exits. E.G. co-working spaces, international desks, Service Fee facilities, advisory, me
Slide 18: Portfolio
PORTFOLIO 3
Slide 19: Our Focus Areas
OUR FOCUS AREAS PHARMACEUTICALS BIOTECH NUTRACEUTICALS Synthesis phase of active Preclinical or phase 1 Between TRL 3 substance achieved or clinical clinical phase. and TRL 7. validation achieved. R&D TECH/AI MEDTECH Artificial Intelligence applied Between TRL 3 to bio-health sector. and TRL 7. 19
Slide 20: AI as a Translational Accelerator
AI AS A TRANSLATIONAL ACCELERATOR By embedding AI across MedTech and Drug Development, Cube Labs advances innovation, optimizes pre-clinical pathways, and strengthens translational impact. • Predictive analytics • Data integration • Decision support • Target & biomarker insights AI RX • Molecule pri
Slide 21: Spin-off Portfolio
SPIN-OFF PORTFOLIO PHARMACEUTICALS PHARMACEUTICALS PHARMACEUTICALS Regenerative Solutions for the technologies against treatment of rare Development of natural osteoarthritis and diseases, which occur and synthetic molecules for diabetes, obesity Funded by Funded by related diseases. They rarely and
Slide 22: Spin-off Portfolio
SPIN-OFF PORTFOLIO NUTRACEUTICALS NUTRACEUTICALS COSMETICS Development of Pioneering dual- bioactive Molecules Myrtoviva aims to component technology derived from green tea innovate the field of combining a catechins with anti- food supplements and biocompatible carrier oxidant and anti- cosmetic pr
Slide 23: Spin-off Portfolio
SPIN-OFF PORTFOLIO MEDTECH MEDTECH MEDTECH Biocompatible, biodegradable, and in A spray-on bandage situ cross-linkable capable of detecting hydrogels that adhere the early signs of to both soft and hard Development of bacterial infections tissues, enabling technologies for through a color change. co
Slide 24: Spin-off Portfolio
SPIN-OFF PORTFOLIO MEDTECH MEDTECH MEDTECH Innovative thermo- graphic imaging Technologies to embedded in a bandage improve visibility during Development of bio- for non-invasive vascular cardiac procedures and sensors for diagnostic, assessment. development of veterinary, Enhancing patient protocol
Slide 25: Beyond Venture Building: A New B2C Platform
BEYOND VENTURE BUILDING: A NEW B2C PLATFORM On July 24, 2026, Serescentia S.r.l. was established as a wholly owned subsidiary of Cube Labs to build, through M&A, an industrial platform focused on longevity, wellness and healthy aging. The company will identify and acquire high-potential SMEs in the
Slide 26: A Dynamic Portfolio with Built-in Upside
A DYNAMIC PORTFOLIO WITH BUILT-IN UPSIDE A well established and diversified company portfolio. A diversified venture-building platform, with value distributed across its portfolio and a growth profile. 154.02 Aggregate economic value of 13 M€ portfolio companies analyzed* • Valuation as of December
Slide 27: IPO
IPO 4
Slide 28: Listing IPO EGM Pro
LISTING IPO EGM PRO Number of shares pre-IPO 15,000,000 Shares newly issued 5,875,260 Number of outstanding shares 20,875,260 Free Float 28.79%* IPO Date March 21, 2023 Issue Price (€) 2.00 Market Cap (€/M) @ IPO 34,105 EGM Market EGM PRO Title update since IPO to 08/10/2026 +13% As of December 31,
Slide 29: EGM Pro Performance
EGM PRO PERFORMANCE Price per Share at IPO: 2€ [IPO March 2023] As of 08 October 2026. Source: Yahoo Finance API. 29
Slide 30: EGM Pro Benchmark
EGM PRO BENCHMARK NAME SYMBOL INDUSTRY PRICE MTD% YTD% YOY% MARKET CAP (M€) ABC Company ABC.MI Industrials 3.9 0 5.51 13.35 124.2 Acquazzurra ACQ.MI Advertising Agency 10.5 0 0 0 27.1 BolognaFiere BF.MI Consumer Discretionary 1.25 0 0 0 243.5 Cogefeed CGF.MI Energy 1.25 0 37.36 60.26 6.4 Creactives
Slide 31: Company Portfolio Value Breakdown
COMPANY PORTFOLIO VALUE BREAKDOWN ESTIMATED PORTFOLIO OF INVESTEE COMPANIES Intermonte, independent corporate broker, identifies significant growth potential for the company. NAV The dynamic NAV per share is projected to be €4.34 (subject to the full subscription of the €4 million capital increase l
Slide 32: Capital Increase
CAPITAL 5 INCREASE
Slide 33: Capital Increase
CAPITAL INCREASE € 4,000,000.00 The Extraordinary Shareholders’ Meeting of Cube Labs S.p.A. approved the delegation to the Board of Directors to increase the share capital, for consideration, in one or more tranches and on a divisible or indivisible basis, for a maximum total amount of €15 million,
Slide 34: Resources Allocation Strategy
RESOURCES ALLOCATION STRATEGY The capital increase will support the development of Serescentia, Italy’s first longevity-focused platform, positioned to capture one of the key trends shaping the Life Sciences sector and accelerate the industrial value creation of Cube Labs’ pipeline. Cube Labs in-hou
Slide 35: Financial Results
SLINSAY TIWIDSNVNIA
Slide 36: Balance Sheet
BALANCE SHEET Balance sheet (€/000) FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 H1 2026 Intangible asset 10 9 15 344 1,161 1,039 807 703 Tangible asset 2 2 3 2 1 6 6 6 Financial asset 349 51,744 52,108 52,312 53,104 53,736 56,087 57,109 Assets 361 51,755 52,126 52,657 54,266 54,781 56,90
Slide 37: Income Statement
INCOME STATEMENT Income statement (€/000) FY 2020 FY 2021 FY 2022 FY2023 FY 2024 FY 2025 H1 2026 Value of production 950 1,127 1,143 1,637 2,108 2,910 1,745 Var YoY% +67.3% +18.6% +1.42% +43.2% +28,8% +38% +21.8% Raw materials (2) (5) (3) (3) (5) (6) (2) Services (410) (571) (903) (1,745) (1,895) (1
Slide 38: ESG Impact
tovdwiosa /.
Slide 39: Democratization of Life Sciences: The A's
DEMOCRATIZATION OF LIFE SCIENCES: THE 5 A's A ffordability The extent to which a patient’s financial ability matches the cost of the service and/or care. Availability The availability of necessary resources such as personnel, technology, and care to meet the patient's needs. Accessibility How easily
Slide 40: Democratization: The Venture Builder's Role
DEMOCRATIZATION: THE VENTURE BUILDER'S ROLE COST CONTAINMENT BRIDGING STRATEGIES ETHICAL THE GAP Reducing healthcare costs through investments in FUNDING BETWEEN SCIENCE SOURCES preventive care, digital AND MARKET health technologies, Partnering with Advancing scientific and personalized investors w
Slide 41: Appendix: Team and SAB
APPENDIX: 8 TEAM AND SAB
Slide 42: Board of Directors
BOARD OF DIRECTORS Filippo Surace Renato Del Grosso Massimo Fiocchi Chairman & CEO Chief Strategy Officer Chief Financial Officer • Serial entrepreneur and innovator with 30+ years of • 17+ years’ experience in market access and • Certified accountant with extensive experience experience in the medi
Slide 43: Executive Leadership
EXECUTIVE LEADERSHIP Neil Thomas Chris Hentschel Natalie Pankova Chief Business Officer Chief Scientific Officer Chief Operating Officer • Partner in Ventac Partners since 2012 with • Molecular biologist and Co-founder of The Ulysses executive roles in their portfolio companies. Advisory Group. • Do
Slide 44: Executive Management
EXECUTIVE MANAGEMENT Daria Brambilla Giorgia Bellantonio Fabio Scognamiglio Scientific Head of Head of People Vice-President, Finance Venture Companies and Culture • Global HR leader with experience in driving • Consolidated experience in biochemistry, sustainable business performance, creating • Te
Slide 45: Strategic Advisory Board
STRATEGIC ADVISORY BOARD Yossi Bornstein Adam Broncel Slawomyr Chomik • Co-founder and former GP, Biomed Venture Capital Fund • Over 35 years in Israeli & International biomed industry • Founder of Poland Ventures • Over 20 years experience in the pharmaceutical industry • CEO and Founder of Shizim
Slide 46: Strategic Advisory Board
STRATEGIC ADVISORY BOARD Pierre A. Morgon Mikael Oerum Fintan Walton • CEO of MRGN Advisors • 40 years of experience in the pharmaceutical, • Regional Partner for Switzerland at Mérieux Equity • CEO and Founder, PharmaVentures, a premier transaction advisory biotech and finance sectors firm Partners
Slide 47: Get in Touch!
GET IN TOUCH! Cube Labs S.p.A. Via G. Caccini, 1 00198 – Rome, Italy www.cube-labs.com info@cube-labs.com